Cara Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Cara Therapeutics is Chris Posner, benoemd in Nov2021, heeft een ambtstermijn van 6.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.92M, bestaande uit 24.9% salaris en 75.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.22% van de aandelen van het bedrijf, ter waarde $ 36.68K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 5.3 jaar.
Belangrijke informatie
Chris Posner
Algemeen directeur
US$2.9m
Totale compensatie
| Percentage CEO-salaris | 24.9% |
| Dienstverband CEO | 3yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues
Nov 01
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jul 18We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$96m |
| Jun 30 2024 | n/a | n/a | -US$111m |
| Mar 31 2024 | n/a | n/a | -US$123m |
| Dec 31 2023 | US$3m | US$728k | -US$119m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$84m |
| Dec 31 2022 | US$3m | US$700k | -US$85m |
| Sep 30 2022 | n/a | n/a | -US$89m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$93m |
| Dec 31 2021 | US$10m | US$116k | -US$88m |
| Sep 30 2021 | n/a | n/a | US$24m |
| Jun 30 2021 | n/a | n/a | US$8m |
| Mar 31 2021 | n/a | n/a | US$14m |
| Dec 31 2020 | US$280k | n/a | US$8m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$115m |
| Mar 31 2020 | n/a | n/a | -US$113m |
| Dec 31 2019 | US$302k | n/a | -US$106m |
| Sep 30 2019 | n/a | n/a | -US$98m |
| Jun 30 2019 | n/a | n/a | -US$85m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$494k | n/a | -US$74m |
Compensatie versus markt: De totale vergoeding ($USD 2.92M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).
Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.
CEO
Chris Posner (54 yo)
3yrs
Tenure
US$2,922,469
Compensatie
Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3yrs | US$2.92m | 0.22% $ 36.7k | |
| Chief Financial Officer | 2.2yrs | US$1.24m | 0.015% $ 2.4k | |
| Co-Founder & Senior Advisor | 3yrs | US$10.20m | geen gegevens | |
| Chief Compliance Officer | 8yrs | US$1.59m | 0.15% $ 24.9k | |
| Manager of Investor Relations | no data | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CARA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.3yrs | US$2.92m | 0.22% $ 36.7k | |
| Independent Chairman & Lead Independent Director | 14.3yrs | US$519.99k | 0.20% $ 33.5k | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 10.3yrs | US$272.49k | 0.087% $ 14.6k | |
| Independent Director | 1.3yrs | US$376.01k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$262.49k | 0.094% $ 15.7k | |
| Independent Director | 2yrs | US$254.99k | 0.059% $ 9.9k |
5.3yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CARA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).